Browsing Tag
Jefferies
60 posts
Willdan (WLDN) completes $285m Mantis acquisition, but can new earnings offset debt costs?
Willdan Group has completed its $285 million acquisition of Mantis Innovation, adding an energy management business expected to generate $120 million in annual net revenue. The purchase expands its commercial and industrial capabilities, but the financing structure and anticipated 2027 earnings contribution will determine whether the deal improves shareholder returns.
Perrigo (PRGO) agrees to sell $380m infant formula business for $40m upfront as impairment looms
Perrigo has agreed to sell its US infant formula business to MeridianMade for up to $175 million, although only $40 million is payable at closing. The planned divestiture could improve margins and reduce future manufacturing investment, but a substantial impairment charge and weak growth in its remaining consumer health business complicate the turnaround.
RAPP stock gains on RAP-219 clinical success as Wall Street weighs modest treatment benefit
Rapport Therapeutics' RAP-219 trial lifts RAPP stock as investors weigh its bipolar mania potential. Discover the Phase 3 outlook and market risks.
Tungsten Mining (ASX: TGN) appoints Jefferies as A$274m Watershed funding push accelerates
Tungsten Mining NL has appointed Jefferies to identify strategic investors for the A$274 million Watershed Project while a separate debt-financing process advances, signalling that the company is building a multi-source funding package rather than relying on another conventional equity raising.
LG Electronics India (NSE: LGEINDIA) jumps 9.6% after 27% Q1 profit growth
LG Electronics India surged 9.6% after Q1 profit rose 27%. Can premium demand and Sri City growth support LGEINDIA's 64x P/E?
Vestas Wind Systems (CPH: VWS) shares jump nearly 19% as Q2 profit beat drives full-year guidance upgrade
Vestas Wind Systems' Q2 EBIT of €446m cleared consensus by 117% and lifted 2026 margin guidance to 7-9%, but management flags Q2 as unusually strong.
Strathcona Resources (TSX: SCR) posts record free cash flow as heavy oil pure-play strategy delivers first full quarter test
Strathcona Resources posts record C$296M Q2 free cash flow as Meota Central first steam and Cold Lake reliability set the second-half production test.
Braveheart Bio IPO targets $1.2bn valuation as HCM drug race heats up
Braveheart Bio is seeking up to $318.8 million in its Nasdaq IPO, but investors must decide whether its cardiac myosin inhibitor can compete in an increasingly crowded hypertrophic cardiomyopathy market.
KKR takes Integer private for $5.7bn as device manufacturing growth slows
KKR’s $5.7 billion Integer deal offers a 52% premium as weaker near-term device sales contrast with durable manufacturing demand.
General Dynamics beats Q2 estimates, raises 2026 guidance on record backlog
General Dynamics beat Q2, raised full-year EPS guidance to $16.80-$16.90 and hit a record $136.5B backlog, yet shares fell 3.1% on supply chain concerns.